A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma

Investigational New Drugs

Volumn 32, Issue 4, 2014, Pages 739-745

  De Jesus Acosta, Ana ^a   Laheru, Daniel ^a   Maitra, Anirban ^a,c   Arcaroli, John ^b   Rudek, Michelle A ^a   Dasari, Arvind ^c   Blatchford, Patrick J ^b   Quackenbush, Kevin ^b   Messersmith, Wells ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gamma secretase inhibitor; Notch signaling; Pancreatic cancer; Pharmacokinetics

Indexed keywords

GAMMA SECRETASE INHIBITOR; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; 2,2-DIMETHYL-N-(6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-N'-(2,2,3,3,3-PENTAFLUOROPROPYL)MALONAMIDE; ANTINEOPLASTIC AGENT; BENZAZEPINE DERIVATIVE; ENZYME INHIBITOR; SECRETASE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASCITES; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; KIDNEY DYSFUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PAIN; PANCREAS ADENOCARCINOMA; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PANCREATIC NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC AGENTS; BENZAZEPINES; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 84904550068     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0083-8     Document Type: Article

References (19)

1. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817-1825
2. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691-1703
3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 15(6):2403-2413 (Pubitemid 27251144)
4. Gittes GK (2009) Developmental biology of the pancreas: a comprehensive review. Dev Biol 326(1):4-35
5. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4(6):437-450 (Pubitemid 38050041)
6. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS et al (2003) Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3(6):565-576 (Pubitemid 36808651)
7. De La OJ, Murtaugh LC (2009) Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling. Cell Cycle 8(12):1860-1864
8. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV, Gurumurthy S, Deshpande V, Kenific C, Settleman J et al (2009) Inhibition of gamma-secretase activity inhibits tumor progression in a mousemodel of pancreatic ductal adenocarcinoma. Gastroenterology 136(5):1741.e6-1749.e6
9. Ristorcelli E, Beraud E, Mathieu S, Lombardo D, Verine A (2009) Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles. Int J Cancer J Int Cancer 125(5):1016-1026
10. Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, Mohammad RM (2009) TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res 69(7):2757-2765
11. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH (2009) Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69(6):2400-2407
12. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, Matsui W, Eberhart CG, Maitra A, Feldmann G (2009) Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res 15(7):2291-2301
13. Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M et al (2014) A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs 32(2):243-249
14. Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H et al (2012) A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer 48(7):997-1003
15. Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T et al (2013) A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer 109(4):943-949
16. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI et al (2012) Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 30(19):2348-2353
17. Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ et al (2013) A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Investig New Drugs 31(5):1182-1191
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
19. Wu J, Wiegand R, LoRusso P, Li J (2011) Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a gamma-secretase inhibitor targeting Notch signaling, in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 879(19):1537-1543